Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

Vaccines are pivotal for control of the coronavirus disease (COVID-19) pandemic. Patients with inflammatory bowel diseases (IBDs) treated with antitumor necrosis factor (TNF)-α have lower serologic response after two COVID-19 vaccine doses. Data regarding a third vaccine dose are scarce. An Israeli...

Descripción completa

Detalles Bibliográficos
Autores principales: Edelman-Klapper, Hadar, Rabinowitz, Keren Masha, Zittan, Eran, Shitrit, Ariella Bar-Gil, Goren, Idan, Avni-Biron, Irit, Ollech, Jacob E., Lichtenstein, Lev, Banai-Eran, Hagar, Yanai, Henit, Snir, Yifat, Pauker, Maor H., Friedenberg, Adi, Levy-Barda, Adva, Broitman, Yelena, Ben Zvi, Haim, Perets, Tsachi-Tsadok, Eliakim, Rami, Barkan, Revital, Goren, Sophy, Cohen, Dani, Dotan, Iris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386081/
https://www.ncbi.nlm.nih.gov/pubmed/37515078
http://dx.doi.org/10.3390/vaccines11071263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386081/
https://www.ncbi.nlm.nih.gov/pubmed/37515078
http://dx.doi.org/10.3390/vaccines11071263

Ejemplares similares